Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

Martin Benedikt; Abderrahim Oulhaj; Ursula Rohrer; M. Manninger; Norbert Tripolt; Peter N Pferschy; M. Faisal; Markus Wallner; Ewald Kolesnik; Marianne Gwechenberger; Martin Martinek; Michael Nürnberg; Franz Xaver Roithinger; Clemens Steinwender; Johannes Widkal; Simon Leiter; Andreas Zirlik; Markus Stühlinger; Daniel Scherr; Harald Sourij; Dirk von Lewinski

doi:10.1056/EVIDoa2400147

Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

Martin Benedikt, Abderrahim Oulhaj, Ursula Rohrer, M. Manninger, Norbert Tripolt, Peter N Pferschy, M. Faisal, Markus Wallner, Ewald Kolesnik, Marianne Gwechenberger, Martin Martinek, Michael Nürnberg, Franz Xaver Roithinger, Clemens Steinwender, Johannes Widkal, Simon Leiter, Andreas Zirlik, Markus Stühlinger, Daniel Scherr, Harald SourijDirk von Lewinski

Clinical Research Institute for Cardiovascular and Metabolic Diseases

Research output: Contribution to journal › Article › peer-review

Abstract

In this multicenter, double-blind, randomized, placebo-controlled trial, we investigated the effects of ertugliflozin on arrhythmic burden among patients with heart failure with an ejection fraction less than 50%. All patients had an implantable cardioverter-defibrillator (ICD) with or without a cardiac resynchronization therapy device (CRT-D) and were randomized (1:1) to receive either ertugliflozin 5 mg once daily or placebo. The primary end point was the number of incident sustained (>30 seconds) ventricular tachycardia or ventricular fibrillation events from baseline to week 52. Secondary end points included the total number of non-sustained ventricular tachycardias, appropriate ICD therapies, changes in N-terminal pro-brain-type natriuretic peptide (NTproBNP) levels, and the number of heart failure hospitalizations.

Original language	English
Number of pages	11
Journal	NEJM Evidence
Volume	3
Issue number	10
DOIs	https://doi.org/10.1056/EVIDoa2400147
Publication status	Published - Sept 2024

Fields of science

302 Clinical Medicine

Access to Document

10.1056/EVIDoa2400147

Cite this

Benedikt, M., Oulhaj, A., Rohrer, U., Manninger, M., Tripolt, N., Pferschy, P. N., Faisal, M., Wallner, M., Kolesnik, E., Gwechenberger, M., Martinek, M., Nürnberg, M., Roithinger, F. X., Steinwender, C., Widkal, J., Leiter, S., Zirlik, A., Stühlinger, M., Scherr, D., ... von Lewinski, D. (2024). Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds. NEJM Evidence, 3(10). https://doi.org/10.1056/EVIDoa2400147

@article{e8e72979c76347a6b8cf5b4b40c4346d,

title = "Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds",

abstract = "In this multicenter, double-blind, randomized, placebo-controlled trial, we investigated the effects of ertugliflozin on arrhythmic burden among patients with heart failure with an ejection fraction less than 50%. All patients had an implantable cardioverter-defibrillator (ICD) with or without a cardiac resynchronization therapy device (CRT-D) and were randomized (1:1) to receive either ertugliflozin 5 mg once daily or placebo. The primary end point was the number of incident sustained (>30 seconds) ventricular tachycardia or ventricular fibrillation events from baseline to week 52. Secondary end points included the total number of non-sustained ventricular tachycardias, appropriate ICD therapies, changes in N-terminal pro-brain-type natriuretic peptide (NTproBNP) levels, and the number of heart failure hospitalizations.",

author = "Martin Benedikt and Abderrahim Oulhaj and Ursula Rohrer and M. Manninger and Norbert Tripolt and Pferschy, {Peter N} and M. Faisal and Markus Wallner and Ewald Kolesnik and Marianne Gwechenberger and Martin Martinek and Michael N{\"u}rnberg and Roithinger, {Franz Xaver} and Clemens Steinwender and Johannes Widkal and Simon Leiter and Andreas Zirlik and Markus St{\"u}hlinger and Daniel Scherr and Harald Sourij and {von Lewinski}, Dirk",

year = "2024",

month = sep,

doi = "10.1056/EVIDoa2400147",

language = "English",

volume = "3",

journal = "NEJM Evidence",

number = "10",

}

Benedikt, M, Oulhaj, A, Rohrer, U, Manninger, M, Tripolt, N, Pferschy, PN, Faisal, M, Wallner, M, Kolesnik, E, Gwechenberger, M, Martinek, M, Nürnberg, M, Roithinger, FX, Steinwender, C, Widkal, J, Leiter, S, Zirlik, A, Stühlinger, M, Scherr, D, Sourij, H & von Lewinski, D 2024, 'Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds', NEJM Evidence, vol. 3, no. 10. https://doi.org/10.1056/EVIDoa2400147

TY - JOUR

T1 - Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

AU - Benedikt, Martin

AU - Oulhaj, Abderrahim

AU - Rohrer, Ursula

AU - Manninger, M.

AU - Tripolt, Norbert

AU - Pferschy, Peter N

AU - Faisal, M.

AU - Wallner, Markus

AU - Kolesnik, Ewald

AU - Gwechenberger, Marianne

AU - Martinek, Martin

AU - Nürnberg, Michael

AU - Roithinger, Franz Xaver

AU - Steinwender, Clemens

AU - Widkal, Johannes

AU - Leiter, Simon

AU - Zirlik, Andreas

AU - Stühlinger, Markus

AU - Scherr, Daniel

AU - Sourij, Harald

AU - von Lewinski, Dirk

PY - 2024/9

Y1 - 2024/9

N2 - In this multicenter, double-blind, randomized, placebo-controlled trial, we investigated the effects of ertugliflozin on arrhythmic burden among patients with heart failure with an ejection fraction less than 50%. All patients had an implantable cardioverter-defibrillator (ICD) with or without a cardiac resynchronization therapy device (CRT-D) and were randomized (1:1) to receive either ertugliflozin 5 mg once daily or placebo. The primary end point was the number of incident sustained (>30 seconds) ventricular tachycardia or ventricular fibrillation events from baseline to week 52. Secondary end points included the total number of non-sustained ventricular tachycardias, appropriate ICD therapies, changes in N-terminal pro-brain-type natriuretic peptide (NTproBNP) levels, and the number of heart failure hospitalizations.

AB - In this multicenter, double-blind, randomized, placebo-controlled trial, we investigated the effects of ertugliflozin on arrhythmic burden among patients with heart failure with an ejection fraction less than 50%. All patients had an implantable cardioverter-defibrillator (ICD) with or without a cardiac resynchronization therapy device (CRT-D) and were randomized (1:1) to receive either ertugliflozin 5 mg once daily or placebo. The primary end point was the number of incident sustained (>30 seconds) ventricular tachycardia or ventricular fibrillation events from baseline to week 52. Secondary end points included the total number of non-sustained ventricular tachycardias, appropriate ICD therapies, changes in N-terminal pro-brain-type natriuretic peptide (NTproBNP) levels, and the number of heart failure hospitalizations.

U2 - 10.1056/EVIDoa2400147

DO - 10.1056/EVIDoa2400147

M3 - Article

VL - 3

JO - NEJM Evidence

JF - NEJM Evidence

IS - 10

ER -